Seyla Azoz, in her article “Are We Prepared for the CDK4/6 Revolution With HR+/HER2− Breast Cancers?: The Importance of Patient Adherence to Adjuvant Therapies,” demonstrates deep expertise in patient needs and the critical challenges of medication adherence in oncology. She highlights that while CDK4/6 inhibitors are revolutionizing the treatment of HR+/HER2− breast cancer, their full potential is hindered by poor adherence to adjuvant endocrine therapy (AET).

Azoz identifies key factors impacting adherence, including side effects, inadequate patient education, lack of coordinated care, and insufficient psychosocial support. Drawing from extensive research and patient advocate discussions, she proposes innovative, patient-centered solutions such as:

• Behavioral and psychosocial interventions, including nurse-led coaching and digital tools tailored to individual patient needs.

• Remote patient monitoring with bi-directional communication to enhance support.

• Personalized education programs to improve patient understanding of treatment benefits and side effects.

There are many other components to the multipronged approach that can and will be investigated, and it is incumbent on us to ensure no stone is left unturned in the quest to help patients find methods to improve medication adherence. Given the great promise of the CDK4/6 therapies for breast cancer, we must hope this call to arms results in long-term solutions being identified, allowing the full benefits of these therapies to be realized globally.

Azoz underscores the role of digital health innovations, AI, and behavioral science in improving adherence, advocating for scalable, patient-driven solutions rather than a technology-first approach. By integrating real-time monitoring, AI-driven patient support, and behavioral insights, Azoz champions a multifaceted, patient-centric model to optimize treatment outcomes and reduce the financial burden of non-adherence in healthcare.